Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Denmark
/
Pharmaceuticals & Biotech
/
H. Lundbeck
HLUN B
H. Lundbeck
Global Pricing Controls Will Erode CNS Drug Portfolios
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 12 Analysts
Published
26 Jun 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
DKK 38.00
1.6% overvalued
intrinsic discount
16 Aug
DKK 38.60
Loading
1Y
-11.4%
7D
9.5%
Author's Valuation
DKK 38.0
1.6% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
DKK 38.0
1.6% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-5b
25b
2014
2017
2020
2023
2025
2026
2028
Revenue DKK 24.8b
Earnings DKK 4.1b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
1.34%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
4.92%
Calculation
DKK 4.12b
Earnings '28
x
10.84x
PE Ratio '28
=
DKK 44.63b
Market Cap '28
DKK 44.63b
Market Cap '28
/
1.02b
No. shares '28
=
DKK 43.65
Share Price '28
DKK 43.65
Share Price '28
Discounted to 2025 @ 4.92% p.a.
=
DKK 37.80
Fair Value '25